Eckert & Ziegler SE is a leading German provider of isotope technology for medical, scientific, and industrial applications, with a strong emphasis on cancer therapy, nuclear imaging, and industrial r... Eckert & Ziegler SE is a leading German provider of isotope technology for medical, scientific, and industrial applications, with a strong emphasis on cancer therapy, nuclear imaging, and industrial radiometry. The company operates through key segments including Medical, which supplies pharmaceutical-quality radioactive ingredients and products for cancer treatment and diagnosis; Isotope Products, its primary revenue generator, manufacturing standards and radiation sources for medical and industrial uses; and Other, covering holding activities. Notable offerings encompass brachytherapy implants for prostate cancer and uveal melanomas, GA-68 generators, radiopharmaceuticals, sealed radiation sources for imaging and gauging, and bulk isotopes. Headquartered in Berlin with over 1,100 employees, Eckert & Ziegler SE generates most revenue from Europe, supplemented by North America, Asia-Pacific, and other regions. Listed in the TecDAX index since its 1999 IPO, the company has expanded globally through strategic acquisitions, solidifying its role in advancing nuclear medicine and radiotherapy solutions. It supports the growing radiopharmaceutical sector, including hard-to-produce isotopes vital for targeted therapies.
Financial Fundamentals data not yet covered for Eckert & Ziegler
We have not yet reviewed Eckert & Ziegler's disclosures for Financial Fundamentals data.
If this data is relevant to your work, you can submit a data coverage request and our team
will investigate the company's disclosures and capture the data if available.